Program Leaders

UWCCC项目领导层的几次变动将增强其翻译潜力。 迈克尔·古尔德博士担任癌症遗传学项目负责人。古尔德医生收到了他的 从威斯康星大学获得博士学位，然后在阿贡国家实验室获得博士后奖学金。 他于1978年加入UWCCC的教职员工，并在整个职业生涯中广泛工作，以整合 乳腺癌病因学和化学预防的基础实验室研究，包括基础研究和翻译研究 项目。通过动物模型，他正在寻找预防乳腺癌的基因。一旦确定，这些 基因将更好地了解修饰基因的作用和癌症风险，并提供靶点 用于抗癌药物的开发。他之前曾在癌症中心担任过多个职位， 包括领导一个乳腺癌项目，最近是病因学和化学预防的负责人 程序。他目前的个人研究兴趣以及他促进合作的历史 翻译研究使他成为领导这个项目的理想人选。 作为该项目的负责人，古尔德博士正在重新组织重点，包括三个领域。第一个是 哺乳动物和人类的遗传学。这一领域的中心目标是利用比较遗传学和基因组学 更好地了解癌症的病因及其进展。这部作品被翻译成人类的形式 风险评估和癌症预防。第二个领域是统计遗传学和信息学。 开发新的统计和信息学方法来绘制已测序的基因组图将是一个主要的焦点，因为 以及开发针对复杂数据集的独特分析方法。第三个领域是身体基因组学 这将为在基因组范围内获取癌症基因组数据开发新的方法。 古尔德博士通过组织面向任务的小组会议以及 提供教育和探索机会的有限数量的大型小组会议和务虚会 潜在的协作战略。他还促进了介绍计划成员的教育研讨会 到新的UWCCC共享资源和仪器。他将促进已建立的重要合作 成员遗传学计划、化学预防计划和癌症控制计划之间的联系 以促进翻译项目间的研究。为此，古尔德博士将10%的精力投入到领导力上 程序。 Hasam Mukhtar博士已担任化学预防计划的联合负责人。他收到了他的 1971年在印度坎普尔的坎普尔大学获得生物化学博士学位。他在哈佛大学接受了博士后培训 在佐治亚医学院，他对解毒酶的兴趣受到了激发。在进一步追查之后 在NIH从事这一领域的工作后，他成为凯斯西储大学的教员，并将 新陈代谢活化和解毒的专业知识，以探索调控癌症发生的方法。他的工作有 现在扩展到饮食与癌症的研究，并重点关注饮食物质对癌症的化学预防。 作为化学预防计划的联合负责人，穆赫塔尔博士将领导和鼓励识别 具有化学预防功效的化合物，促进了与翻译科学家的合作，以识别 行动机制和潜在目标，并发起与医生的合作，以探索 化学预防的治疗策略。他将为这项活动付出5%的努力。 道格拉斯·麦克尼尔博士将取代詹姆斯·斯图尔特博士担任实验治疗计划的联合负责人。 麦克尼尔博士加入了威斯康星大学的教职，担任 医学于2001年7月问世。1986年，他在惠特曼学院获得化学和音乐学士学位。然后他 在芝加哥大学获得医学科学家培训奖后接受研究生培训，并获得 1992年获得生物化学和分子生物学博士学位，1994年获得医学博士学位。然后他完成了一项内部调查 华盛顿大学临床研究人员之路上的医学住院医师，以及 2000年在华盛顿大学和弗雷德·哈钦森癌症研究中心获得肿瘤学奖学金。 在获得临床研究员资格后，他加入了华盛顿大学的肿瘤疫苗小组，工作了四年。 在威斯康星大学，麦克尼尔博士继续专注于前列腺癌的免疫学研究。 实验室研究试图确定前列腺组织表达的由淋巴细胞识别的蛋白质 前列腺癌和慢性炎症性前列腺炎患者，以及确定疫苗策略 能够引起前列腺特异性炎症的。临床研究探索免疫反应 能够摧毁前列腺癌细胞的能力可以通过以下方式在前列腺癌患者中诱导 疫苗。这项研究的长期目标是开发前列腺癌辅助治疗的疫苗。 癌症。 麦克尼尔博士被选为该计划的共同负责人，以解决明显缺乏计划整合的问题 采用免疫疗法的成员与该计划的其余部分进行了接触。他的临床 研究活动的重点是前列腺癌和免疫学方法的使用，特别是 用于治疗前列腺癌的疫苗。他的实验室正在开发使用细胞和动物的疫苗 靶向前列腺酸性磷酸酶和雄激素受体的模型。他还在领导临床试验，以 在前列腺癌患者中评估这些方法。麦克尼尔博士将带来他可观的基础科学 和临床专业知识用于实验治疗方案，并帮助整合重要的 该计划的免疫学优势。他将为这项活动付出5%的努力。

Several changes in the Leadership of UWCCC Programs will strengthen their translational potential. Dr. Michael Gould has assumed the role of Program Leader for Cancer Genetics. Dr. Gould received his Ph.D. from the University of Wisconsin followed by a postdoctoral fellowship at Argonne National Laboratory. He joined the faculty of the UWCCC in 1978 and has worked extensively throughout his career to integrate basic laboratory studies in breast cancer etiology and chemoprevention, including both basic and translational projects. Using animal models, he is searching for genes that prevent breast cancer. Once identified, these genes will provide a better understanding of the role of modifier genes and cancer risk and also provide targets for the development of anticancer drugs. He has previously served in many positions in the Cancer Center, including leadership of a breast cancer program and most recently leader of the Etiology and Chemoprevention Program. His current personal research interests as well as his history of fostering collaborations for translational research make him an ideal candidate to assume leadership of this program. As leader of this Program Dr. Gould is reorganizing the emphasis to include three areas. The first is mammalian and human genetics. The central goal of this area is using comparative genetics and genomics to better understand the etiology of cancer and its progression. This work is translated to humans in the form of risk estimation and cancer prevention. The second area is that of statistical genetics and informatics. Developing new statistical and informatic approaches to map the sequenced genomes will be a major focus as well as developing unique methods of analysis for complex data sets. The third area is physical genomics which will develop novel approaches for the acquisition of cancer genomics data on a genome wide scale. Dr. Gould facilitates Program interactions by organizing small group meetings that are task oriented as well as a limited number of large group meetings and retreats that provide education and the opportunity to explore potential collaborative strategies. He also facilitates educational workshops that introduce Program members to new UWCCC shared resources and instrumentation. He will foster the established important collaborative ties between the members Genetics Program, the Chemoprevention Program and the Cancer Control Program to facilitate translational inte-rprogrammatic research. Dr. Gould devotes 10% effort to leadership for this Program. Dr. Hasam Mukhtar has assumed the role of co-leader for the Chemoprevention Program. He received his PhD in Biochemistry from Kanpur University in Kanpur India in 1971. He did postdoctoral training at the Medical College of Georgia where his interest in detoxification enzymes was stimulated. After pursuing further work in this field at NIH, he became a faculty member at Case Western Reserve University and combined the expertise of metabolic activation and detoxification to explore ways to regulate carcinogenesis. His work has now extended to the study of diet and cancer and a focus on dietary substances for cancer chemoprevention. As co-leader of the Chemoprevention Program, Dr. Mukhtar will lead and stimulate the efforts to identify compounds with chemopreventive efficacy, foster the collaborations with translational scientists to identify mechanisms of action and potential targets, and initiate collaborations with physicians to explore options for treatment strategies for chemoprevention. He will devote 5% effort to this activity. Dr. Douglas McNeel will replace Dr. James Stewart as co-leader of the Experimental Therapeutics Program. Dr. McNeel joined the faculty at the University of Wisconsin as an Assistant Professor in the Department of Medicine in July 2001. He received his BA in Chemistry and Music at Whitman College in 1986. He then pursued graduate training under a Medical Scientist Training Award at the University of Chicago, and received his PhD (Biochemistry and Molecular Biology) in 1992 and MD in 1994. He then completed an Internal Medicine residence at the University of Washington on a Clinical Investigator Pathway, and a Medical Oncology fellowship at the University of Washington and Fred Hutchinson Cancer Research Center in 2000. After his clinical fellowship, he joined the Tumor Vaccine Group at the University of Washington for four years. At the University of Wisconsin, Dr. McNeel continues to focus on the immunology of prostate cancer. Laboratory studies seek to identify proteins expressed by prostate tissue that are recognized by lymphocytes in patients with prostate cancer and chronic inflammatory prostatitis, as well as identify vaccine strategies capable of inducing prostate-specific inflammation. Clinical studies explore whether immune responses capable of destroying prostate cancer cells can be elicited in patients with prostate cancer by means of vaccines. The long-range goal of this research is to develop vaccines for the adjuvant treatment of prostate cancer. Dr. McNeel was selected to co-lead this program to address an apparent lack of integration of program members who were employing immunologic therapeutic approached with the rest of the program. His clinical and research activities focus on prostate cancer and the use of immunological approaches, especially vaccines, for the treatment of prostate cancer. His laboratory is developing vaccines using cellular and animal models targeting prostatic acid phosphatase and androgen receptor. He also is leading clinical trials to evaluate these approaches in prostate cancer patients. Dr. McNeel will bring his considerable basic science and clinical expertise to the Experimental Therapeutics program and help to integrate the important immunological strengths of the program. He will devote 5% effort to this activity.